Houston software startup raises $12.5M series B

money moves

Codenotary's software enables tools for notarization and verification of the software development life cycle. Photo via Getty Images

Houston-based Codenotary, whose technology helps secure software supply chains, has raised $12.5 million in a series B round. Investors in the round include Swiss venture capital firm Bluwat and French venture capital firm Elaia.

The $12.5 million round follows a series A round that was announced in 2020, with total funding now at $18 million.

Codenotary, formely known as vChain, says the fresh round of money will be used to accelerate product development, and expand marketing and sales worldwide. Today, the startup has 100-plus customers, including some of the world’s largest banks.

Codenotary’s co-founders are CEO Moshe Bar and CTO Dennis Zimmer. They started the company in 2018.

Bar co-founded Qumranet, which developed the Linux KVM hypervisor. A hypervisor creates and runs virtual machines. Software provider Red Hat purchased Qumranet in 2008 for $127 million. Before that, he founded hypervisor company XenSource, which cloud computing company Citrix Systems bought in 2007 for $500 million.

“Codenotary offers a solution which allows organizations to quickly identify and track all components in their DevOps cycle and therefore restore trust and integrity in all their myriad applications,” Pascal Blum, senior partner at Bluwat, says in a news release.

The SolarWinds software supply chain hack in 2020 and the more recent emergence of Log4j vulnerabilities have brought the dangers of software lifecycle attacks to the forefront, Bar says. Now, he says, more and more companies are looking for ways to prove the legitimacy of the software that they produce.

Codenotary is the primary contributor to immudb, the an open-source, enterprise-class database with data immutability, or stability, designed to meet the demands of highly used applications.

Houston-based vChain, creator of CodeNotary, has raised $7 million in a series A financing round. Pexels

Houston software company closes $7 million series A

money moves

A Houston tech company that has optimizes a notarization system for coding professionals has closed a multimillion-dollar round of funding.

Houston-based vChain, which created the CodeNotary Open Source code trust solution, has raised $7 million in a series A funding round. Paris-based Elaia Partners led the investment round, and other contributors include Zug, Switzerland-based Bluwat and Seattle-based Acequia Capital.

"CodeNotary today processes over 9 million code and container authentications every single month," says CEO Moshe Bar in a news release. "We believe this is proof that the market demands secure and simple to use trust solutions for the modern DevOps environment."

Bar, who previously founded of XenSource and Qumranet, co-founded vChain with Dennis Zimmer in late 2018. The company released its first product in April of last year, and has a secondary office in Amsterdam.

"With much more at stake both financially and reputationally, companies must act quickly to bring trust and security into their DevOps process," Bar continues. "CodeNotary was created to solve this issue and ensure that only trusted code and data run in production."

The software tool, which is used to ensure code is securely transmitted throughout the entire development to production process, has several platform integrations and works with languages such as JavaScript, Python, Go, Java, and more.

"Our vision is a digital world where every object has a globally unique and meaningful identity," says Zimmer, who serves as CTO, in the release. "For the first time, DevOps teams can completely secure the integrity of their Continuous Integration and Continuous Delivery pipelines. Not just internally, but also across companies, contributors and contractors."

The money raised will be used to continue the development of the tool as the DevOps industry continues to grow within the market.

"The DevOps industry is a rapidly growing billion-dollar market transforming itself very quickly," says Marc Rougier, partner at Elaia, in the release. "The importance of DevOps for any organization is obvious, no matter its size. However, the main reason for hesitation in DevOps transformation is a lack of trust. vChain is the leading solution to bring trust to DevOps and we're thrilled to be a part of it."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings